Evidence-based insights into peptide protocols, safety research, and optimization strategies. Built on clinical rigor, powered by community knowledge.
Get weekly insights on peptide protocols, safety updates, and optimization strategies delivered to your inbox.
No spam. Unsubscribe anytime. Clinical rigor, always.
Deep dives into peptide science — evidence-graded, honestly reported
RFK said peptides are back. The FDA hasn't published the rule change yet. Here's what's actually happening.
The FDA's 2026 peptide reclassification is a regulatory process, not a completed rule change. Seven compounds face PCAC review in July 2026, legal access requires a prescription, and the grey market remains unchanged until the FDA publishes.
Comprehensive outcome research with safety data and practical protocol references
The best immune peptides aren't the ones that turn the system up. They're the ones that teach it when to hold still.
Immune regulation is about homeostasis, not amplification. Thymosin Alpha-1 acts as a thermostat — pushing Th1 when the system is under-responsive, pushing T-regs when it's over-firing. Bioregulators work upstream at the level of gene expression. Thymosin Beta-4 regenerates across organ systems. Selank bridges the brain-immune axis. Understanding when to use each — and when not to — is the difference between peptide therapy and peptide tourism.
Detailed compound profiles with mechanisms, safety data, and dosing protocols
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "will
Evidence-based supplement stacks designed to support your peptide protocols
The biochemical cofactors your body needs to support Retatrutide therapy.
Evidence-based supplement companion for Retatrutide — for the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
Evidence-graded testosterone profiles by ester and formulation, with safety data and peptide alternatives
Two routes, one molecule: how undecanoate rewrote the oral testosterone playbook and what the TRAVERSE trial actually proved about heart safety.
Testosterone undecanoate is the only ester available as both a long-acting injectable (Aveed, Nebido) and a twice-daily oral (Jatenzo, Kyzatrex). Its lymphatic absorption bypasses the liver entirely, solving the hepatotoxicity problem that killed earlier oral steroids. The TRAVERSE trial confirmed cardiovascular non-inferiority, but flagged atrial fibrillation and kidney injury signals that demand ongoing monitoring.
Cardiac peptide therapy isn't science fiction — Tβ4 has completed Phase 2 in acute MI (NCT05984134), and SS-31 sits in advanced-phase trials for mitochondrial heart disease.
A plain-English look at the peptides being investigated for cardiovascular repair — Thymosin β4 for post-infarct tissue regeneration, elamipretide for mitochondrial membrane stability, and the adjacent vascular-bioregulator layer.
Inflammation isn't just something to suppress — peptides like ARA-290 and KPV suggest you can reprogram the response entirely.
A plain-English look at the peptides being investigated for inflammation and tissue repair — what the evidence shows, what's still missing, and where the safety line sits.
Tirzepatide's insulin-sensitivity effect comes mostly from direct metabolic reprogramming, not weight loss. MOTS-c bypasses the insulin receptor entirely. The Khavinson bioregulators target β-cell regeneration via epigenetics. The three stories land at very different evidence grades — and the highest-impact decision in the whole class is sourcing.
Peptide therapy for insulin sensitivity now spans three distinct mechanistic classes: incretin agonists (GLP-1, tirzepatide, retatrutide) acting at the hormonal layer, mitochondrial-derived peptides (MOTS-c) acting at the cellular-energy layer via AMPK, and epigenetic bioregulators (Khavinson peptides, Pancragen) attempting to restore gene expression in β-cells. Weight loss explains only 13–21% of tirzepatide's HOMA-IR improvement — the rest is direct metabolic reprogramming. MOTS-c is an exercise mimetic in early trials. Bioregulators are a Russian-literature frontier awaiting Western replication. Sourcing is the biggest preventable harm in the whole class.
Peptide-based gut healing splits across four mechanistically distinct compounds acting on different layers of the gastrointestinal barrier. The animal dossier is extensive; the human evidence is sparse; the regulatory posture is sceptical. An honest map of what is known, what is guessed, and where the practical safety decisions actually are.
BPC-157 drives angiogenesis and tissue repair. Larazotide antagonises zonulin to re-seal tight junctions. KPV suppresses NF-κB-driven inflammation. LL-37 reinforces the antimicrobial and mucus defence. The mechanism map is coherent. The human trial record — Larazotide's discontinued Phase III, BPC-157's three small pilots, the FDA's Category 2 classification — is sobering. Grey-market sourcing, not the peptides themselves, is the dominant source of documented harm.
GLP-1 agonists became a cultural phenomenon because they deliver dramatic short-term weight loss. The honest framing is chronic-disease pharmacology — effective while taken, compensation when withdrawn, best used alongside the nutritional foundation the drug amplifies.
Peptide-based appetite suppression splits across four classes — incretin agonists (semaglutide, tirzepatide, retatrutide), amylin analogs (cagrilintide), hypothalamic peptides (BRP), and growth-hormone fragments (AOD-9604). The multi-pathway arms race is producing larger weight losses, the weight-regain-on-discontinuation pattern is producing harder questions, and the nutritional foundation is producing the difference between therapeutic weight loss and iatrogenic frailty.
The first synthetic testosterone ester (1936), with a 2-4.5 day half-life that demands daily or EOD dosing. What the clinical data says about the fertility paradox, rapid washout safety, microdosing, and why this 'relic' is the precision tool of modern endocrinology.
Evidence-graded profile of testosterone propionate: the fastest-acting injectable ester, its fertility paradox from murine data, the washout safety net for women and diagnostics, PIP solutions through microdosing, circadian alignment, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester outside the US, with a 4.5-7 day half-life that demands weekly dosing for stable levels. What the clinical data says about the hepcidin hijack, erythrocytosis, and why dosing frequency matters more than dose size.
Evidence-graded profile of testosterone enanthate: the hepcidin mechanism behind erythrocytosis, DHT and the scrotal paradox, dosing frequency pharmacokinetics, the TRAVERSE prostate saturation model, age-stratified risk, and peptide alternatives.
The most prescribed testosterone ester in the US, with an 8-day half-life that makes it the backbone of modern TRT. What the clinical data actually says about how to use it.
Evidence-graded profile of testosterone cypionate: pharmacokinetics, subcutaneous vs intramuscular data, the TRAVERSE trial's cardiovascular findings, age-stratified risk, and where peptides fit alongside.
35+
Articles
18
Categories